


**File S5:** HIV viral splicing ( $\Delta$ RQ) of the three different study groups at baseline and endpoint in resting CD4 T cells-depleted PBMCs (rCD4 T- PBMCs)


rCD4 T- PBMCs						
BASELINE						
Groups	Unspliced Mean ± SEM	<i>p</i>	Single spliced Mean ± SEM	<i>p</i>	Multiple spliced Mean ± SEM	<i>p</i>
HIV+	30.87 ± 11.54	0.013	63.25 ± 44.69	0.841	2.80 ± 2.80	0.692
HIV+/HCV-	979.10 ± 343.61		1282.70 ± 838.93		0 ± 0	
HIV+/HCV+	2784.43 ± 2473.01		2869.30 ± 2414.90		0.03 ± 0.02	
ENDPOINT						
Groups	Unspliced Mean ± SEM	<i>p</i>	Single spliced Mean ± SEM	<i>p</i>	Multiple spliced Mean ± SEM	<i>p</i>
HIV+	17908.59 ± 11459.20	0.310	2645.84 ± 1774.06	0.332	509.98 ± 509.98	0.956
HIV+/HCV-	52861.64 ± 22163.51		315926.84 ± 1774.06		6.80 ± 6.80	
HIV+/HCV+	106632.50 ± 74472.90		75566.19 ± 52720.25		518.14 ± 512.64	

Note: HIV, Human Immunodeficiency Virus; HCV, Hepatitis C Virus; rCD4+ T cells, resting CD4+ T cells; rCD4 T- PBMCs, resting CD4 T cells-depleted PBMCs; SEM, standard error of the mean. A Kruskal-Wallis H-test was used to compare differences between study groups for the different forms of splicing. Statistical significance was defined as  $P < 0.05$  (2-tailed).

## BASELINE rCD4 T- PBMCs



## ENDPOINT rCD4 T- PBMCs



Note: HIV, Human Immunodeficiency Virus; HCV, Hepatitis C Virus; rCD4+ T cells, resting CD4+ T cells; rCD4 T- PBMCs, resting CD4 T cells-depleted PBMCs; baseline, time of the study when HIV+/HCV+ individuals had never been treated for hepatitis; endpoint, time of the study when HIV+/HCV+ subjects had cleared HCV by treatment with direct-acting antivirals. Bars represent  $\Delta RQ$  arithmetic mean and standard error of the mean. A Kruskal-Wallis H-test was used to determine whether the three study groups behaved as independent populations. Statistical significance was defined as  $P < 0.05$  (2-tailed).